Skip to main content

Articles

Page 5 of 48

  1. Sodium-glucose cotransporter 2 (SGLT2) inhibition reduces cardiovascular events in type 2 diabetes (T2DM) and is associated with a reduction in left ventricular (LV) mass index. However, the impact on right ve...

    Authors: Bradley Sarak, Subodh Verma, C. David Mazer, Hwee Teoh, Adrian Quan, Richard E. Gilbert, Shaun G. Goodman, Karan Bami, Otávio R. Coelho-Filho, Vineeta Ahooja, Djeven P. Deva, Vinay Garg, Sumeet Gandhi, Kim A. Connelly and Andrew T. Yan
    Citation: Cardiovascular Diabetology 2021 20:200
  2. Patients with Covid-19 place new challenges on the management of type 2 diabetes, including the questions of whether glucose-lowering therapy should be adjusted during infection and how to manage a return to n...

    Authors: Leszek Czupryniak, Dror Dicker, Roger Lehmann, Martin Prázný and Guntram Schernthaner
    Citation: Cardiovascular Diabetology 2021 20:198
  3. Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic disease and independently affects the development of cardiovascular (CV) disease. We investigated whether hepatic steatosis and/...

    Authors: Jiyun Park, Gyuri Kim, Hasung Kim, Jungkuk Lee, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur and Jae Hyeon Kim
    Citation: Cardiovascular Diabetology 2021 20:197
  4. The impressive results of recent clinical trials with glucagon-like peptide-1 receptor agonists (GLP-1Ra) and sodium glucose transporter 2 inhibitors (SGLT-2i) in terms of cardiovascular protection prompted a ...

    Authors: Andrea Natali, Lorenzo Nesti, Domenico Tricò and Ele Ferrannini
    Citation: Cardiovascular Diabetology 2021 20:196
  5. The risk of heart failure among diabetic individuals is high, even under tight glycemic control. The correlates and mediators of heart failure risk in individuals with diabetes need more elucidation in large p...

    Authors: Matti A. Vuori, Jaakko Reinikainen, Stefan Söderberg, Ellinor Bergdahl, Pekka Jousilahti, Hugh Tunstall-Pedoe, Tanja Zeller, Dirk Westermann, Susana Sans, Allan Linneberg, Licia Iacoviello, Simona Costanzo, Veikko Salomaa, Stefan Blankenberg, Kari Kuulasmaa and Teemu J. Niiranen
    Citation: Cardiovascular Diabetology 2021 20:195
  6. The REWIND trial demonstrated cardiovascular (CV) benefits to patients with type 2 diabetes and multiple CV risk factors or established CV disease. This exploratory analysis evaluated the degree to which the e...

    Authors: Manige Konig, Matthew C. Riddle, Helen M. Colhoun, Kelley R. Branch, Charles M. Atisso, Mark C. Lakshmanan, Reema Mody, Sohini Raha and Hertzel C. Gerstein
    Citation: Cardiovascular Diabetology 2021 20:194
  7. Liver stiffness measurement (LSM, which reflects fibrosis) and controlled attenuation parameter (CAP, which reflects steatosis), two parameters derived from hepatic transient elastography (TE), have scarcely b...

    Authors: Claudia R. L. Cardoso, Cristiane A. Villela-Nogueira, Nathalie C. Leite and Gil F. Salles
    Citation: Cardiovascular Diabetology 2021 20:193
  8. The prognostic role of hyperglycemia in patients with myocardial infarction and obstructive coronary arteries (MIOCA) is acknowledged, while data on non-obstructive coronary arteries (MINOCA) are still lacking...

    Authors: Pasquale Paolisso, Alberto Foà, Luca Bergamaschi, Francesco Angeli, Michele Fabrizio, Francesco Donati, Sebastiano Toniolo, Chiara Chiti, Andrea Rinaldi, Andrea Stefanizzi, Matteo Armillotta, Angelo Sansonetti, Ilenia Magnani, Gianmarco Iannopollo, Paola Rucci, Gianni Casella…
    Citation: Cardiovascular Diabetology 2021 20:192
  9. A prothrombotic state is a typical feature of type 2 diabetes mellitus (T2DM). Apart from increased platelet reactivity, endothelial dysfunction, hyperfibrinogenemia, and hypofibrinolysis are observed in T2DM....

    Authors: Agata Hanna Bryk-Wiązania and Anetta Undas
    Citation: Cardiovascular Diabetology 2021 20:191
  10. Insulin resistance (IR), evaluation of which is difficult and complex, is closely associated with cardiovascular disease. Recently, various IR surrogates have been proposed and proved to be highly correlated w...

    Authors: Qi Zhao, Yu-Jing Cheng, Ying-Kai Xu, Zi-Wei Zhao, Chi Liu, Tie-Nan Sun and Yu-Jie Zhou
    Citation: Cardiovascular Diabetology 2021 20:190
  11. A meta-analysis is presented of cardiovascular outcome trials (CVOTs) comparing glucagon-like peptide-1 receptor agonists (GLP-1RA) versus placebo on cardiorenal outcomes in patients with type 2 diabetes melli...

    Authors: Dario Giugliano, Lorenzo Scappaticcio, Miriam Longo, Paola Caruso, Maria Ida Maiorino, Giuseppe Bellastella, Antonio Ceriello, Paolo Chiodini and Katherine Esposito
    Citation: Cardiovascular Diabetology 2021 20:189
  12. Apolipoprotein (Apo) A1 and Apo B are strongly associated with the risk of atherosclerotic cardiovascular disease (ASCVD). However, the relationship between the Apo B/A1 ratio and the morphology of coronary vu...

    Authors: Fuxue Deng, Danni Li, Lei Lei, Qiang Yang, Qing Li, Hongtao Wang, Jie Deng, Qiangsun Zheng and Wei Jiang
    Citation: Cardiovascular Diabetology 2021 20:188
  13. Patients with type 2 diabetes (T2D) may experience frequent body weight changes over time. The prognostic impact of these weight changes (gains or losses) requires further study.

    Authors: João Pedro Ferreira, Patrick Rossignol, George Bakris, Cyrus Mehta, William B. White and Faiez Zannad
    Citation: Cardiovascular Diabetology 2021 20:187
  14. Identification of the effective subtypes of treatment for heart failure (HF) is an essential topic for optimizing treatment of the disorder. We hypothesized that the beneficial effect of SGLT2 inhibitors (SGLT...

    Authors: Kenya Kusunose, Takumi Imai, Atsushi Tanaka, Kaoru Dohi, Kazuki Shiina, Takahisa Yamada, Keisuke Kida, Kazuo Eguchi, Hiroki Teragawa, Yasuchika Takeishi, Nobuyuki Ohte, Hirotsugu Yamada, Masataka Sata and Koichi Node
    Citation: Cardiovascular Diabetology 2021 20:186
  15. Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome with sex-specific pathophysiology. Estrogen deficiency is believed to be responsible for the development of HFpEF in women. Ho...

    Authors: Ke Shi, Meng-Xi Yang, Shan Huang, Wei-Feng Yan, Wen-Lei Qian, Yuan Li, Ying-Kun Guo and Zhi-Gang Yang
    Citation: Cardiovascular Diabetology 2021 20:185
  16. Authors: Federico Biscetti, Giovanni Tinelli, Maria Margherita Rando, Elisabetta Nardella, Andrea Leonardo Cecchini, Flavia Angelini, Giuseppe Straface, Marco Filipponi, Vincenzo Arena, Dario Pitocco, Antonio Gasbarrini, Massimo Massetti and Andrea Flex
    Citation: Cardiovascular Diabetology 2021 20:184

    The original article was published in Cardiovascular Diabetology 2021 20:114

  17. Insulin resistance is associated with the incidence of diabetes and cardiovascular diseases such as myocardial infarction. The ratio of triglycerides (TG) to high-density lipoprotein cholesterol (HDL-C) (TG/HD...

    Authors: Joungyoun Kim, Sang-Jun Shin, Ye-Seul Kim and Hee-Taik Kang
    Citation: Cardiovascular Diabetology 2021 20:183
  18. Basement membrane (BM) accumulation is a hallmark of micro-vessel disease in diabetes mellitus (DM). We previously reported marked upregulation of BM components in internal thoracic arteries (ITAs) from type 2...

    Authors: Lasse Bach Steffensen, Xenia Emilie Sinding Iversen, Rasmus Søgaard Hansen, Pia Søndergaard Jensen, Anne-Sofie Faarvang Thorsen, Jes Sanddal Lindholt, Lars Peter Schødt Riber, Hans Christian Beck and Lars Melholt Rasmussen
    Citation: Cardiovascular Diabetology 2021 20:182
  19. Recent treatment guidelines support the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes and cardiovascular disease based on the results of cardiovascular outcome tria...

    Authors: Lisanne C. A. Smidt, Frank L. J. Visseren, Wendela L. de Ranitz-Greven, Hendrik M. Nathoe, L. Jaap Kappelle, Gert J. de Borst, Harold W. de Valk and Jan Westerink
    Citation: Cardiovascular Diabetology 2021 20:181
  20. Patients with diabetes mellitus (DM) have a higher prevalence of heart failure (HF) than those without it. Approximately 40 % of HF patients have DM and they tend to have poorer outcomes than those without DM....

    Authors: Se Yong Jang, Jieun Jang, Dong Heon Yang, Hyun-Jai Cho, Soo Lim, Eun-Seok Jeon, Sang Eun Lee, Jae-Joong Kim, Seok-Min Kang, Sang Hong Baek, Myeong-Chan Cho, Dong-Ju Choi, Byung-Su Yoo, Kye Hun Kim, Sue K. Park and Hae-Young Lee
    Citation: Cardiovascular Diabetology 2021 20:180
  21. Type 2 diabetes mellitus is common in patients undergoing dialysis. However, the association between anti-diabetic drug use and survival outcomes is rarely discussed. We aimed to investigate whether continued ...

    Authors: Shih-Hsiang Ou, Hsin-Yu Chen, Nai-Wen Fang, Chun-Hao Yin, Chien-Liang Chen and Jin-Shuen Chen
    Citation: Cardiovascular Diabetology 2021 20:179
  22. Type 2 diabetes causes cardio-renal complications and is treated with different combination therapies. The renal hemodynamics profile of such combination therapies has not been evaluated in detail.

    Authors: Christian Ott, Susanne Jung, Manuel Korn, Dennis Kannenkeril, Agnes Bosch, Julie Kolwelter, Kristina Striepe, Peter Bramlage, Mario Schiffer and Roland E. Schmieder
    Citation: Cardiovascular Diabetology 2021 20:178
  23. It remains uncertain if prior use of oral anticoagulants (OACs) in COVID-19 outpatients with multimorbidity impacts prognosis, especially if cardiometabolic diseases are present. Clinical outcomes 30-days afte...

    Authors: José Miguel Rivera-Caravaca, Stephanie L. Harrison, Benjamin J. R. Buckley, Elnara Fazio-Eynullayeva, Paula Underhill, Francisco Marín and Gregory Y. H. Lip
    Citation: Cardiovascular Diabetology 2021 20:176
  24. Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of a deterioration in heart failure (HF) and mortality in patients with a broad range of cardiovascular risks. Recent guidelines recommend cons...

    Authors: Atsushi Tanaka, Shigeru Toyoda, Takumi Imai, Kazuki Shiina, Hirofumi Tomiyama, Yasushi Matsuzawa, Takahiro Okumura, Yumiko Kanzaki, Katsuya Onishi, Arihiro Kiyosue, Masami Nishino, Yasushi Sakata and Koichi Node
    Citation: Cardiovascular Diabetology 2021 20:175
  25. Although both a history of cerebrovascular disease (CVD) and glucose abnormality are risk factors for CVD, few large studies have examined their association with subsequent CVD in the same cohort. Thus, we com...

    Authors: Momoko Oe, Kazuya Fujihara, Mayuko Harada-Yamada, Taeko Osawa, Masaru Kitazawa, Yasuhiro Matsubayashi, Takaaki Sato, Yuta Yaguchi, Midori Iwanaga, Hiroyasu Seida, Takaho Yamada and Hirohito Sone
    Citation: Cardiovascular Diabetology 2021 20:174
  26. There is a high incidence of cardiovascular disease in diabetes. Weight variability has been reported as independent risk factor for cardiovascular disease in the general population and preliminarily also in p...

    Authors: Antonio Ceriello, Giuseppe Lucisano, Francesco Prattichizzo, Björn Eliasson, Stefan Franzén, Ann-Marie Svensson and Antonio Nicolucci
    Citation: Cardiovascular Diabetology 2021 20:173
  27. Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-induced infection, the cause of coronavirus disease 2019 (COVID-19), is characterized by acute clinical pathologies, including various coagulopathie...

    Authors: Etheresia Pretorius, Mare Vlok, Chantelle Venter, Johannes A. Bezuidenhout, Gert Jacobus Laubscher, Janami Steenkamp and Douglas B. Kell
    Citation: Cardiovascular Diabetology 2021 20:172
  28. Risk stratification of patients with prediabetes is an unmet clinical need. Here, we examine the utility of subclinical myocardial necrosis assessed by high-sensitivity cardiac troponin T (hs-cTnT) in predicti...

    Authors: Marco Witkowski, Yuping Wu, Stanley L. Hazen and W. H. Wilson Tang
    Citation: Cardiovascular Diabetology 2021 20:171
  29. Randomized controlled trials showed that sodium/glucose cotransporter-2 inhibitors (SGLT2i) protect the heart and kidney in an array of populations with type 2 diabetes (T2D) and increased cardiorenal risk. Ho...

    Authors: Meir Schechter, Cheli Melzer-Cohen, Aliza Rozenberg, Ilan Yanuv, Gabriel Chodick, Avraham Karasik, Mikhail Kosiborod and Ofri Mosenzon
    Citation: Cardiovascular Diabetology 2021 20:169
  30. Compared to individuals without type 2 diabetes mellitus, the relative increase in cardiovascular mortality is much higher in women than in men in individuals with type 2 diabetes mellitus.

    Authors: Marcello Ricardo Paulista Markus, Till Ittermann, Sabine Schipf, Martin Bahls, Matthias Nauck, Henry Völzke, Raul Dias Santos, Annette Peters, Tanja Zeller, Stephan Burkhard Felix, Ramachandran S. Vasan, Barbara Thorand, Elisabeth Steinhagen-Thiessen and Marcus Dörr
    Citation: Cardiovascular Diabetology 2021 20:168
  31. There is a controversy over the association between obesity and the risk of renal events in patients with type 2 diabetes mellitus (T2DM). Furthermore, whether body weight (BW) loss following sodium glucose co...

    Authors: Yi-Hsin Chan, Shao-Wei Chen, Tze-Fan Chao, Yi-Wei Kao, Chien-Ying Huang and Pao-Hsien Chu
    Citation: Cardiovascular Diabetology 2021 20:167
  32. Nesfatin-1, a novel adipokine and dipeptidyl peptidase-4 (DPP4), a mam malian serine protease, are potent factors of atherosclerosis. In the present cross-sectional study, we investigated whether the plasma ne...

    Authors: Nikolaos P. E. Kadoglou, Emmanouil Korakas, Stylianos Lampropoulos, Eirini Maratou, George Kassimis, Nikolaos Patsourakos, Panagiotis Plotas, Paraskevi Moutsatsou and Vaia Lambadiari
    Citation: Cardiovascular Diabetology 2021 20:166
  33. COVID-19 diabetic adults are at increased risk of severe forms irrespective of obesity. In patients with type-II diabetes, fat distribution is characterized by visceral and ectopic adipose tissues expansion, r...

    Authors: Franck Phan, Samia Boussouar, Olivier Lucidarme, Mohamed Zarai, Joe-Elie Salem, Nadjia Kachenoura, Khaoula Bouazizi, Etienne Charpentier, Yasmine Niati, Hasnae Bekkaoui, Zahir Amoura, Alexis Mathian, Olivier Benveniste, Patrice Cacoub, Yves Allenbach, David Saadoun…
    Citation: Cardiovascular Diabetology 2021 20:165
  34. High-risk coronary artery plaque (HRP) is associated with increased risk of acute coronary syndrome.

    Authors: Laurits Juhl Heinsen, Gokulan Pararajasingam, Thomas Rueskov Andersen, Søren Auscher, Hussam Mahmoud Sheta, Helle Precht, Jess Lambrechtsen and Kenneth Egstrup
    Citation: Cardiovascular Diabetology 2021 20:164
  35. Patients with diabetes mellitus (DM) are at increased risk of developing heart failure (HF). The “Heart OMics in AGEing” (HOMAGE) trial suggested that spironolactone had beneficial effect on fibrosis and cardi...

    Authors: Job A. J. Verdonschot, João Pedro Ferreira, Pierpaolo Pellicori, Hans-Peter Brunner-La Rocca, Andrew L. Clark, Franco Cosmi, Joe Cuthbert, Nicolas Girerd, Beatrice Mariottoni, Johannes Petutschnigg, Patrick Rossignol, John G. F. Cleland, Faiez Zannad and Stephane R. B. Heymans
    Citation: Cardiovascular Diabetology 2021 20:163
  36. In a cohort study performed using primary care databases in a General Practitioners Network, Groenewegen et al. report a clear association between diabetes and incidence of the major chronic progressive heart ...

    Authors: Lucia La Sala and Antonio E. Pontiroli
    Citation: Cardiovascular Diabetology 2021 20:162
  37. Whether differences in circulating long chain acylcarnitines (LCAC) are seen in heart failure (HF) patients with and without diabetes mellitus (DM), and whether these biomarkers report on exercise capacity and...

    Authors: Lauren K. Truby, Jessica A. Regan, Stephanie N. Giamberardino, Olga Ilkayeva, James Bain, Christopher B. Newgard, Christopher M. O’Connor, G. Michael Felker, William E. Kraus, Robert W. McGarrah and Svati H. Shah
    Citation: Cardiovascular Diabetology 2021 20:161
  38. The most recent treatment guidelines for type 2 diabetes (T2D) recommend sodium-glucose cotransporter 2 (SGLT2) inhibitors should be considered preferentially in patients with T2D with either a high cardiovasc...

    Authors: Atsushi Tanaka, Michio Shimabukuro, Hiroki Teragawa, Yosuke Okada, Toshinari Takamura, Isao Taguchi, Shigeru Toyoda, Hirofumi Tomiyama, Shinichiro Ueda, Yukihito Higashi and Koichi Node
    Citation: Cardiovascular Diabetology 2021 20:160
  39. Randomized, controlled cardiovascular outcome trials may not be fully representative of the management of patients with type 2 diabetes across different geographic regions. We conducted analyses of data from t...

    Authors: Kamlesh Khunti, Mikhail Kosiborod, Dae Jung Kim, Shun Kohsaka, Carolyn S. P. Lam, Su-Yen Goh, Chern-En Chiang, Jonathan E. Shaw, Matthew A. Cavender, Navdeep Tangri, Josep Franch-Nadal, Reinhard W. Holl, Marit E. Jørgensen, Anna Norhammar, Johan G. Eriksson, Francesco Zaccardi…
    Citation: Cardiovascular Diabetology 2021 20:159
  40. Functional mitral regurgitation (FMR) is one of the most common heart valve diseases in diabetes and may increase left ventricular (LV) preload and aggravate myocardial stiffness. This study aimed to investiga...

    Authors: Yi Zhang, Wei-feng Yan, Li Jiang, Meng-ting Shen, Yuan Li, Shan Huang, Ke shi and Zhi-gang Yang
    Citation: Cardiovascular Diabetology 2021 20:158
  41. The fibroblast growth factor (FGF) 21-adiponectin pathway is involved in the regulation of insulin resistance. However, the relationship between the FGF21-adiponectin pathway and type 2 diabetes in humans is u...

    Authors: Dan Liu, Liang Wu, Qiongmei Gao, Xiaoxue Long, Xuhong Hou, Lingling Qian, Jiacheng Ni, Qichen Fang, Huating Li and Weiping Jia
    Citation: Cardiovascular Diabetology 2021 20:157
  42. Triglyceride-rich lipoproteins particles (TRLP) and low density lipoprotein particles (LDLP) vary in size. Their association with β-cell function is not well described. We determined associations of TRLP and L...

    Authors: Sara Sokooti, Jose L. Flores-Guerrero, Hiddo J. L. Heerspink, Margery A. Connelly, Stephan J. L. Bakker and Robin P. F. Dullaart
    Citation: Cardiovascular Diabetology 2021 20:156
  43. Metabolic syndrome (MetS) is a multimorbid long-term condition without consensual medical definition and a diagnostic based on compatible symptomatology. Here we have investigated the molecular signature of Me...

    Authors: Chiara Bruzzone, Rubén Gil-Redondo, Marisa Seco, Rocío Barragán, Laura de la Cruz, Claire Cannet, Hartmut Schäfer, Fang Fang, Tammo Diercks, Maider Bizkarguenaga, Beatriz González-Valle, Ana Laín, Arantza Sanz-Parra, Oscar Coltell, Ander López de Letona, Manfred Spraul…
    Citation: Cardiovascular Diabetology 2021 20:155
  44. There is a paucity of global data on cardiovascular disease (CVD) prevalence in people with type 2 diabetes (T2D). The primary objective of the CAPTURE study was to estimate the prevalence of established CVD a...

    Authors: Ofri Mosenzon, Abdullah Alguwaihes, Jose Luis Arenas Leon, Fahri Bayram, Patrice Darmon, Timothy M. E. Davis, Guillermo Dieuzeide, Kirsten T. Eriksen, Tianpei Hong, Margit S. Kaltoft, Csaba Lengyel, Nicolai A. Rhee, Giuseppina T. Russo, Shinichiro Shirabe, Katerina Urbancova and Sergio Vencio
    Citation: Cardiovascular Diabetology 2021 20:154
  45. Obesity and type 2 diabetes are well-known risk factors for heart failure (HF). Although obesity has increased in type 1 diabetes, studies regarding HF in this population are scarce. Therefore, we investigated...

    Authors: Erika B. Parente, Valma Harjutsalo, Carol Forsblom and Per-Henrik Groop
    Citation: Cardiovascular Diabetology 2021 20:153
  46. Pioglitazone use is known to be associated with a reduced risk of recurrent stroke in patients with diabetes mellitus (DM) who have a history of stroke. However, it is unclear whether this benefit extends to p...

    Authors: Junghee Ha, Dong-Woo Choi, Keun You Kim, Chung Mo Nam and Eosu Kim
    Citation: Cardiovascular Diabetology 2021 20:152
  47. Succinate is produced by both host and microbiota, with a key role in the interplay of immunity and metabolism and an emerging role as a biomarker for inflammatory and metabolic disorders in middle-aged adults...

    Authors: Francisco J. Osuna-Prieto, Borja Martinez-Tellez, Lourdes Ortiz-Alvarez, Xinyu Di, Lucas Jurado-Fasoli, Huiwen Xu, Victoria Ceperuelo-Mallafré, Catalina Núñez-Roa, Isabelle Kohler, Antonio Segura-Carretero, José V. García-Lario, Angel Gil, Concepción M. Aguilera, Jose M. Llamas-Elvira, Patrick C. N. Rensen, Joan Vendrell…
    Citation: Cardiovascular Diabetology 2021 20:151
  48. Diabetic patients have an increased predisposition to thromboembolic events, in most cases originating from thrombi in the left atrial appendage (LAA). Remodeling of the LAA, which predisposes to thrombi forma...

    Authors: Or Yosefy, Barucha Sharon, Chana Yagil, Mark Shlapoberski, Alejandro Livoff, Ilana Novitski, Ronen Beeri, Yoram Yagil and Chaim Yosefy
    Citation: Cardiovascular Diabetology 2021 20:149

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Annual Journal Metrics